Graycliff Exploration to Acquire Geologic Data Related to Its Shakespeare Gold Project

Toronto, Ontario–(Newsfile Corp. – February 26, 2026) – Graycliff Exploration Limited (CSE: GRAY) (OTC Pink: GRYCF) (FSE: GE0) (the “Company” or “Graycliff“) is pleased to announce that it has executed an arm’s length asset purchase agreement (the “Agreement“), dated February 26, 2026, with Mona McKinnon (the “Vendor“), contemplating the acquisition (the “Acquisition“) of certain geologic data, core, […]

ALUULA Composites Announces the Engagement of Bristol Capital for Investor Relations Services

Victoria, British Columbia–(Newsfile Corp. – February 26, 2026) – ALUULA Composites Inc. (TSXV: AUUA) (OTCQB: AUUAF) (“ALUULA” or the “Company“), a leading developer of an ultra-light, high performance and recycle-ready composite materials, today announced that it has retained Bristol Capital Ltd. (“Bristol“), a leading investor relations firm specializing in Canadian and U.S. micro- and small-cap

Andean Precious Metals Reports Fourth Quarter and Year-End 2025 Production Results and Provides 2026 Production and Cost Guidance

(All amounts in U.S. dollars unless otherwise indicated) Toronto, Ontario–(Newsfile Corp. – February 26, 2026) – Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) (“Andean” or the “Company“) is pleased to report its operational results for the quarter and year ended December 31, 2025, along with its production, cost, and capital investment guidance for 2026. The Company

QScreen AI Announces Strategic Financing to Advance Commercialization Initiatives Across North America

Toronto, Ontario–(Newsfile Corp. – February 26, 2026) – QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, is pleased to announce a non-brokered private placement. The Company intends to issue (the “Offering”) of up to 10,000,000 units (each, a “Unit”) at a

Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight

The chondrosarcoma market is anticipated to increase during the forecast period (2026-2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies such as Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others, and global healthcare spending, reports DelveInsight. Recently published chondrosarcoma Market Insights report includes a comprehensive understanding

EV Nickel Announces Maiden Mineral Resource Estimate for Gemini North Nickel Zone

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA OR TO US WIRE SERVICES Distinct deposit to CarLang A with significant "Mt. Keith Style" primary sulphide mineralization with higher confirmed nickel recoveries Gemini North Zone Resources total 93.5M tonnes, averaging 0.23% Ni (US$7.35/t NSR cut-off), split between: Indicated Resources of 9.5M tonnes at 0.27% containing

MacroGenics to Participate in Upcoming Investor Conferences

(NASDAQ:MGNX), ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics' President and

Algoma Steel Group Inc. to Announce 2025 Fourth Quarter and Full Year Results March 11, 2026

(NasdaqGM:ASTL),(NasdaqGM:ASTLW),(TSX:ASTL),(TSX:ASTL-WT), SAULT STE. MARIE, Feb. 26, 2026 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of steel plate and hot rolled sheet products, announced today that the Company will release its 2025 fourth quarter and full year financial results after the market closes on

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire February 26, 2026 ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen

Algoma Steel Group Inc. to Announce 2025 Fourth Quarter and Full Year Results March 11, 2026

Algoma Steel Group Inc. to Announce 2025 Fourth Quarter and Full Year Results March 11, 2026 GlobeNewswire February 26, 2026 SAULT STE. MARIE, Feb. 26, 2026 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of steel plate and hot rolled sheet products, announced today

Scroll to Top